A Personalized Cancer Vaccine that Induces Synergistic Innate and Adaptive Immune Responses
Da‐Sol Kuen, Jihye Hong, Suyoung Lee, Choong‐Hyun Koh, Minkyeong Kwak, Byung‐Seok Kim, Byung‐Seok Kim, Mungyo Jung, Yoon‐Joo Kim, Byung‐Sik Cho, Byung‐Soo Kim, Byung‐Soo Kim, Yeonseok Chung
Abstract
Abstract To demonstrate potent efficacy, a cancer vaccine needs to activate both innate and adaptive immune cells. Personalized cancer vaccine strategies often require the identification of patient‐specific neoantigens; however, the clonal and mutational heterogeneity of cancer cells presents inherent challenges. Here, extracellular nanovesicles derived from alpha‐galactosylceramide‐conjugated autologous acute myeloid leukemia (AML) cells (ECNV‐ α GC) are presented as a personalized therapeutic vaccine that activates both innate and adaptive immune responses, bypassing the need to identify patient‐specific neoantigens. ECNV‐ α GC vaccination directly engages with and activates both invariant natural killer T (iNKT) cells and leukemia‐specific CD8 + T cells in mice with AML, thereby promoting long‐term anti‐leukemic immune memory. ECNV‐ α GC sufficiently serves as an antigen‐presenting platform that can directly activate antigen‐specific CD8 + T cells even in the absence of dendritic cells, thereby demonstrating a multifaceted cellular mechanism of immune activation. Moreover, ECNV‐ α GC vaccination results in a significantly lower AML burden and higher percentage of leukemia‐free survivors among cytarabine‐treated hosts with AML. Human AML‐derived ECNV‐ α GCs activate iNKT cells in both healthy individuals and patients with AML regardless of responsiveness to conventional therapies. Together, autologous AML‐derived ECNV‐ α GCs may be a promising personalized therapeutic vaccine that efficiently establishes AML‐specific long‐term immunity without requiring the identification of neoantigens.